DK1007505T3 - Visse 5-alkyl-2-arylaminophenyleddikesyrer og derivater - Google Patents

Visse 5-alkyl-2-arylaminophenyleddikesyrer og derivater

Info

Publication number
DK1007505T3
DK1007505T3 DK98948872T DK98948872T DK1007505T3 DK 1007505 T3 DK1007505 T3 DK 1007505T3 DK 98948872 T DK98948872 T DK 98948872T DK 98948872 T DK98948872 T DK 98948872T DK 1007505 T3 DK1007505 T3 DK 1007505T3
Authority
DK
Denmark
Prior art keywords
derivatives
alkyl
certain
arylaminophenylacetic acids
arylaminophenylacetic
Prior art date
Application number
DK98948872T
Other languages
Danish (da)
English (en)
Inventor
Roger Aki Fujimoto
Leslie Wighton Mcquire
Benjamin Biro Mugrage
Duzer John Henry Van
Daqiang Xu
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26736901&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1007505(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of DK1007505T3 publication Critical patent/DK1007505T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/40—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/42—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton with carboxyl groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by saturated carbon chains
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK98948872T 1997-08-28 1998-08-26 Visse 5-alkyl-2-arylaminophenyleddikesyrer og derivater DK1007505T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6983797P 1997-08-28 1997-08-28
US5780397P 1997-08-28 1997-08-28
PCT/EP1998/005414 WO1999011605A1 (en) 1997-08-28 1998-08-26 Certain 5-alkyl-2-arylaminophenylacetic acids and derivatives

Publications (1)

Publication Number Publication Date
DK1007505T3 true DK1007505T3 (da) 2003-07-21

Family

ID=26736901

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98948872T DK1007505T3 (da) 1997-08-28 1998-08-26 Visse 5-alkyl-2-arylaminophenyleddikesyrer og derivater

Country Status (34)

Country Link
US (5) US6291523B1 (2)
EP (1) EP1007505B1 (2)
JP (1) JP3704470B2 (2)
KR (1) KR100637296B1 (2)
CN (1) CN1140500C (2)
AR (1) AR015157A1 (2)
AT (1) ATE237580T1 (2)
AU (1) AU743371B2 (2)
BR (1) BR9812010B1 (2)
CA (1) CA2298033C (2)
CO (1) CO4960662A1 (2)
CY (1) CY2007020I1 (2)
CZ (1) CZ298522B6 (2)
DE (4) DE122009000013I1 (2)
DK (1) DK1007505T3 (2)
ES (1) ES2197508T3 (2)
FR (1) FR09C0011I2 (2)
HU (1) HU225774B1 (2)
ID (1) ID23953A (2)
IL (2) IL134498A0 (2)
LU (2) LU91346I2 (2)
MY (1) MY127881A (2)
NL (1) NL300379I2 (2)
NO (2) NO326196B1 (2)
NZ (1) NZ502669A (2)
PE (1) PE108099A1 (2)
PL (1) PL194480B1 (2)
PT (1) PT1007505E (2)
RU (1) RU2186762C2 (2)
SI (1) SI1007505T1 (2)
SK (1) SK283773B6 (2)
TR (1) TR200000447T2 (2)
TW (1) TWI250142B (2)
WO (1) WO1999011605A1 (2)

Families Citing this family (140)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040072889A1 (en) * 1997-04-21 2004-04-15 Pharmacia Corporation Method of using a COX-2 inhibitor and an alkylating-type antineoplastic agent as a combination therapy in the treatment of neoplasia
CO4960662A1 (es) * 1997-08-28 2000-09-25 Novartis Ag Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados
ES2234324T3 (es) * 1998-11-02 2005-06-16 MERCK & CO., INC. Combinaciones de un agonista 5ht1b/1d y un inhibidor selectivo de cox-2 para el tratamiento de la migraña.
US20040053900A1 (en) * 1998-12-23 2004-03-18 Pharmacia Corporation Method of using a COX-2 inhibitor and an aromatase inhibitor as a combination therapy
US20040122011A1 (en) * 1998-12-23 2004-06-24 Pharmacia Corporation Method of using a COX-2 inhibitor and a TACE inhibitors as a combination therapy
GB9922830D0 (en) * 1999-09-27 1999-11-24 Novartis Ag Processes
KR100793668B1 (ko) 1999-12-08 2008-01-10 파마시아 코포레이션 강화된 생체이용률을 지닌 고체상 형태의 셀레콕시브
AR030630A1 (es) * 2000-09-11 2003-08-27 Novartis Ag Composiciones farmaceuticas
WO2002040018A1 (en) * 2000-11-14 2002-05-23 Alcon, Inc. Treatment of glaucoma and ocular hypertension
US7656959B2 (en) 2001-04-13 2010-02-02 Agere Systems Inc. Pipelined decision-feedback unit in a reduced-state viterbi detector with local feedback
US20050264906A1 (en) * 2004-05-25 2005-12-01 Haratsch Erich F Method and apparatus for reduced-state Viterbi detection in a read channel of a magnetic recording system
DE10129320A1 (de) * 2001-06-19 2003-04-10 Norbert Mueller Verwendung von COX-2 Inhibitoren zur Behandlung von Schizophrenie, wahnhaften Störungen, affektiven Störungen oder Ticstörungen
US20060167074A1 (en) * 2001-06-19 2006-07-27 Norbert Muller Methods and compositions for the treatment of psychiatric disorders
AR038957A1 (es) 2001-08-15 2005-02-02 Pharmacia Corp Terapia de combinacion para el tratamiento del cancer
AR036312A1 (es) * 2001-08-31 2004-08-25 Novartis Ag Composicion farmaceutica
US6777417B2 (en) 2001-09-10 2004-08-17 Sugen, Inc. 3-(4,5,6,7-tetrahydroindol-2-ylmethylidiene-2-indolinone derivatives as kinase inhibitors
EP1434576A4 (en) 2001-09-13 2006-03-29 Kenneth E Miller METHOD FOR RELIEVING PAIN
US7504231B2 (en) * 2001-09-13 2009-03-17 The Board Of Regents Of The University Of Oklahoma Method of alleviating chronic pain via peripheral inhibition of neurotransmitter synthesis
GB0124459D0 (en) * 2001-10-11 2001-12-05 Novartis Ag Organic compounds
US20050043409A1 (en) * 2001-10-25 2005-02-24 Chen Ying-Nan Pan Combinations comprising a selective cyclooxygenase-2 inhibitor
ATE352319T1 (de) * 2001-11-06 2007-02-15 Novartis Pharma Gmbh Kombination cyclooxygenase-2 inhibitor/ histone deacetylase inhibitor
US20030220374A1 (en) * 2002-01-14 2003-11-27 Pharmacia Corporation Compositions and methods of treatment involving peroxisome proliferator-activated receptor-gamma agonists and cyclooxygenase-2 selective inhibitors
US20030212138A1 (en) * 2002-01-14 2003-11-13 Pharmacia Corporation Combinations of peroxisome proliferator-activated receptor-alpha agonists and cyclooxygenase-2 selective inhibitors and therapeutic uses therefor
GB0201520D0 (en) * 2002-01-23 2002-03-13 Novartis Ag Pharmaceutical uses
US20050123604A1 (en) * 2002-03-07 2005-06-09 Karnachi Anees A. Pharmaceutical compositions
GB0209257D0 (en) * 2002-04-23 2002-06-05 Novartis Ag Organic compounds
CA2487414A1 (en) 2002-06-11 2003-12-18 Nitromed, Inc. Nitrosated and/or nitrosylated cyclooxygenase-2 selective inhibitors, compositions and methods of use
ITMI20021391A1 (it) 2002-06-25 2003-12-29 Nicox Sa Nitroderivati di inibitori della cicloossigenasi-2
EP1531793A1 (en) 2002-07-23 2005-05-25 Novartis AG Ophtalmic ointment composition comprising a drug, an ointment base and a solubiling/dispersing agent
UY27939A1 (es) 2002-08-21 2004-03-31 Glaxo Group Ltd Compuestos
WO2004028448A2 (en) * 2002-09-13 2004-04-08 Miller Kenneth E Method of alleviating pain via inhibition of neurotransmitter synthesis
GB0224198D0 (en) * 2002-10-17 2002-11-27 Novartis Ag Organic compounds
US7632866B2 (en) * 2002-10-21 2009-12-15 Ramot At Tel Aviv University Derivatives of N-phenylanthranilic acid and 2-benzimidazolone as potassium channel and/or neuron activity modulators
US20040147581A1 (en) * 2002-11-18 2004-07-29 Pharmacia Corporation Method of using a Cox-2 inhibitor and a 5-HT1A receptor modulator as a combination therapy
PE20040844A1 (es) * 2002-11-26 2004-12-30 Novartis Ag Acidos fenilaceticos y derivados como inhibidores de la cox-2
US20040204411A1 (en) * 2002-12-17 2004-10-14 Pharmacia Corporation Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of reboxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof
AU2003294883A1 (en) * 2002-12-18 2004-07-09 Novartis Ag Combinations of valsartan with cox-2 inhibitors
US7157577B2 (en) 2003-03-07 2007-01-02 Sugen Inc. 5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors
TWI327913B (en) * 2003-03-12 2010-08-01 Novartis Ag Pharmaceutical composition comprising 5-methyl-2-(2'-chloro-6'-fluoroanilino)phenylacetic acid
US20040220155A1 (en) * 2003-03-28 2004-11-04 Pharmacia Corporation Method of providing a steroid-sparing benefit with a cyclooxygenase-2 inhibitor and compositions therewith
SE0301010D0 (sv) 2003-04-07 2003-04-07 Astrazeneca Ab Novel compounds
US20040220187A1 (en) * 2003-04-22 2004-11-04 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a sodium ion channel blocker for the treatment of pain, inflammation or inflammation mediated disorders
WO2004093816A2 (en) * 2003-04-22 2004-11-04 Pharmacia Corporation Compositions comprising a selective cox-2 inhibitor and a calcium modulating agent
US20060135506A1 (en) * 2003-04-22 2006-06-22 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a calcium modulating agent for the treatment of pain, inflammation or inflammation mediated disorders
WO2004093895A1 (en) * 2003-04-22 2004-11-04 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a potassium ion channel modulator for the treatment of pain, inflammation or inflammation mediated disorders
ES2275218T3 (es) 2003-05-07 2007-06-01 Osteologix A/S Sales de estroncio hidrosolubles para el tratamiento de afecciones de cartilagos y/o huesos.
US20050107387A1 (en) * 2003-05-13 2005-05-19 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a peroxisome proliferator activated receptor agonist for the treatment of ischemic mediated central nervous system disorders
US20050026919A1 (en) * 2003-05-14 2005-02-03 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a cholinergic agent for the treatment of reduced blood flow or trauma to the central nervous system
US7220422B2 (en) 2003-05-20 2007-05-22 Allergan, Inc. Methods and compositions for treating eye disorders
WO2004105699A2 (en) * 2003-05-28 2004-12-09 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a cannabinoid agent for the treatment of central nervous system damage
US20050101597A1 (en) * 2003-07-10 2005-05-12 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitior and a non-NMDA glutamate modulator for the treatment of central nervous system damage
US20050014729A1 (en) * 2003-07-16 2005-01-20 Pharmacia Corporation Method for the treatment or prevention of dermatological disorders with a cyclooxygenase-2 inhibitor alone and in combination with a dermatological treatment agent and compositions therewith
US20050075341A1 (en) * 2003-07-17 2005-04-07 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and an IKK inhibitor for the treatment of ischemic mediated central nervous system disorders or injury
US20050119262A1 (en) * 2003-08-21 2005-06-02 Pharmacia Corporation Method for preventing or treating an optic neuropathy with a cox-2 inhibitor and an intraocular pressure reducing agent
SA04250253B1 (ar) 2003-08-21 2009-11-10 استرازينيكا ايه بي احماض فينوكسي اسيتيك مستبدلة باعتبارها مركبات صيدلانية لعلاج الامراض التنفسية مثل الربو ومرض الانسداد الرئوي المزمن
WO2005018563A2 (en) * 2003-08-22 2005-03-03 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a phosphodiesterase inhibitor for the treatment of ischemic mediated central nervous system disorders or injury
US20050113409A1 (en) * 2003-09-03 2005-05-26 Pharmacia Corporation Method for the prevention or treatment of pain, inflammation and inflammation-related disorders with a Cox-2 selective inhibitor in combination with a nitric oxide-donating agent and compositions therewith
MXPA06003663A (es) * 2003-10-03 2006-06-05 Pharmacia Corp Composiciones de un inhibidor selectivo de la ciclooxigenasa - 2 administrado en condiciones hipotermicas para el tratamiento de trastornos o lesion del sistema nervioso central mediados por isquemicos.
WO2005037266A1 (en) * 2003-10-08 2005-04-28 Novartis Ag Pharmaceutical composition comprising 5-methyl-2-(2’-chloro-6’-fluoroanilino)phenylacetic acid
BRPI0415939A (pt) * 2003-11-12 2007-01-02 Pharmacia & Upjohn Co Llc composições de um inibidor seletivo da ciclooxigenase-2 e um agente de modulação do fator neurotrófico para o tratamento de distúrbios mediados pelo sistema nervoso central
EP1710257A4 (en) 2004-01-07 2011-03-23 Seikagaku Kogyo Co Ltd HYALURONIC ACID DERIVATIVE AND MEDICAMENT CONTAINING THEREOF
KR101179393B1 (ko) * 2004-03-23 2012-09-07 노파르티스 아게 제약 조성물
TW200603792A (en) * 2004-04-23 2006-02-01 Pharmacia & Upjohn Co Llc Monotherapy for the treatment of psoriasis with cyclooxygenase-2 selective inhibitors
US7380199B2 (en) * 2004-05-25 2008-05-27 Agere Systems Inc. Method and apparatus for precomputation and pipelined selection of branch metrics in a reduced-state Viterbi detector
US7653154B2 (en) * 2004-05-25 2010-01-26 Agere Systems Inc. Method and apparatus for precomputation and pipelined selection of intersymbol interference estimates in a reduced-state Viterbi detector
US7487432B2 (en) * 2004-05-25 2009-02-03 Agere Systems Inc. Method and apparatus for multiple step Viterbi detection with local feedback
GB0415320D0 (en) 2004-07-08 2004-08-11 Astrazeneca Ab Novel compounds
GB0416508D0 (en) * 2004-07-23 2004-08-25 Merck Sharp & Dohme Therapeutic agents
GB0418830D0 (en) 2004-08-24 2004-09-22 Astrazeneca Ab Novel compounds
DE102004044827A1 (de) * 2004-09-16 2006-03-23 Bayer Cropscience Ag Jod-phenylsubstituierte cyclische Ketoenole
UY29223A1 (es) 2004-11-23 2006-06-30 Astrazeneca Ab Ácidos fenoxiacéticos sustituidos, composiciones farmacéuticas que los contienen y procesos para su preparación
EP1833795B1 (en) 2004-12-23 2009-03-04 Glaxo Group Limited Pyridine compounds for the treatment of prostaglandin mediated diseases
MX2007010186A (es) * 2005-02-22 2007-11-06 Merial Ltd Metodos para tratar selectivamente desordenes mediados por cox-2 mediante la administracion de gamma-tocoferol.
CA2763671A1 (en) 2005-04-26 2006-11-02 Pfizer Inc. P-cadherin antibodies
WO2006121887A2 (en) * 2005-05-05 2006-11-16 Cook Biotech Incorporated Implantable materials and methods for inhibiting tissue adhesion formation
NZ566774A (en) 2005-09-07 2011-11-25 Pfizer Human monoclonal antibodies to activin receptor-like kinase-1
TW200745003A (en) 2005-10-06 2007-12-16 Astrazeneca Ab Novel compounds
EP1937632A1 (en) 2005-10-06 2008-07-02 Astra Zeneca AB Novel compounds
JP2007275193A (ja) * 2006-04-04 2007-10-25 Fujifilm Corp 光プローブおよび光断層画像化装置
AR061623A1 (es) 2006-06-26 2008-09-10 Novartis Ag Derivados de acido fenilacetico
GB0704407D0 (en) 2007-03-07 2007-04-18 Glaxo Group Ltd Compounds
UA100983C2 (ru) 2007-07-05 2013-02-25 Астразенека Аб Бифенилоксипропановая кислота как модулятор crth2 и интермедиаты
US7943658B2 (en) * 2007-07-23 2011-05-17 Bristol-Myers Squibb Company Indole indane amide compounds useful as CB2 agonists and method
CN101868443A (zh) * 2007-09-20 2010-10-20 特拉维夫大学拉莫特有限公司 N-苯基邻氨基苯甲酸衍生物及其用途
US20090082452A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched lumiracoxib
BRPI0907364A2 (pt) 2008-02-01 2015-07-14 Amira Pharmaceuticals Inc Antagonistas aminoalquilbifenil n,n-disubstituídos de receptores d2 de prostaglandina
WO2009102893A2 (en) 2008-02-14 2009-08-20 Amira Pharmaceuticals, Inc. CYCLIC DIARYL ETHER COMPOUNDS AS ANTAGONISTS OF PROSTAGLANDIN D2 receptors
JP2011513242A (ja) 2008-02-25 2011-04-28 アミラ ファーマシューティカルズ，インク． プロスタグランジンｄ２受容体アンタゴニスト
US8426449B2 (en) 2008-04-02 2013-04-23 Panmira Pharmaceuticals, Llc Aminoalkylphenyl antagonists of prostaglandin D2 receptors
US8071807B2 (en) 2008-07-03 2011-12-06 Panmira Pharmaceuticals, Llc Antagonists of prostaglandin D2 receptors
GB0813142D0 (en) 2008-07-17 2008-08-27 Glaxo Group Ltd Novel compounds
GB0813144D0 (en) 2008-07-17 2008-08-27 Glaxo Group Ltd Novel compounds
GB2463788B (en) 2008-09-29 2010-12-15 Amira Pharmaceuticals Inc Heteroaryl antagonists of prostaglandin D2 receptors
WO2010039977A2 (en) 2008-10-01 2010-04-08 Amira Pharmaceuticals, Inc. Heteroaryl antagonists of prostaglandin d2 receptors
WO2010042652A2 (en) 2008-10-08 2010-04-15 Amira Pharmaceuticals, Inc. Heteroalkyl biphenyl antagonists of prostaglandin d2 receptors
EP2177215A1 (en) 2008-10-17 2010-04-21 Laboratorios Del. Dr. Esteve, S.A. Co-crystals of tramadol and NSAIDs
US8227451B2 (en) * 2008-11-12 2012-07-24 Auspex Pharmaceuticals Phenylacetic acid inhibitors of cyclooxygenase
US8383654B2 (en) 2008-11-17 2013-02-26 Panmira Pharmaceuticals, Llc Heterocyclic antagonists of prostaglandin D2 receptors
WO2011012622A1 (en) 2009-07-30 2011-02-03 Glaxo Group Limited Benzoxazinone derivatives for the treatment of glytl mediated disorders
EP2461809A4 (en) 2009-07-31 2013-06-19 Panmira Pharmaceuticals Llc OPHTHALMIC PHARMACEUTICAL COMPOSITIONS OF DP2 RECEPTOR ANTAGONSITES
US8815917B2 (en) 2009-08-05 2014-08-26 Panmira Pharmaceuticals, Llc DP2 antagonist and uses thereof
WO2011023753A1 (en) 2009-08-27 2011-03-03 Glaxo Group Limited Benzoxazine derivatives as glycine transport inhibitors
EP2521713A4 (en) * 2010-01-06 2013-10-02 Panmira Pharmaceuticals Llc ANTAGONIST OF DP2 AND ITS USES
GB201000685D0 (en) 2010-01-15 2010-03-03 Glaxo Group Ltd Novel compounds
GB201007791D0 (en) 2010-05-10 2010-06-23 Glaxo Group Ltd Novel compounds
GB201007789D0 (en) 2010-05-10 2010-06-23 Glaxo Group Ltd Novel Compound
ES2529233T3 (es) 2010-07-09 2015-02-18 Convergence Pharmaceuticals Limited Compuestos tetrazol como bloqueadores de canales de calcio
RU2439053C1 (ru) * 2010-08-03 2012-01-10 Государственное образовательное учреждение высшего профессионального образования "Пермский государственный университет" Диариламины и способ их получения
US8892989B1 (en) * 2010-08-26 2014-11-18 Clearslide, Inc. Method for searching companies and people
US8900798B2 (en) 2010-10-18 2014-12-02 Eastman Kodak Company On-press developable lithographic printing plate precursors
US20120090486A1 (en) 2010-10-18 2012-04-19 Celin Savariar-Hauck Lithographic printing plate precursors and methods of use
US20120141935A1 (en) 2010-12-03 2012-06-07 Bernd Strehmel Developer and its use to prepare lithographic printing plates
US20120141941A1 (en) 2010-12-03 2012-06-07 Mathias Jarek Developing lithographic printing plate precursors in simple manner
US20120141942A1 (en) 2010-12-03 2012-06-07 Domenico Balbinot Method of preparing lithographic printing plates
EP2665729B1 (en) 2011-01-19 2015-04-01 Convergence Pharmaceuticals Limited Piperazine derivatives as cav2.2 calcium channel blockers
US20120199028A1 (en) 2011-02-08 2012-08-09 Mathias Jarek Preparing lithographic printing plates
CA2848229C (en) 2011-09-16 2019-08-27 Fovea Pharmaceuticals Aniline derivatives, their preparation and their therapeutic application
US8632941B2 (en) 2011-09-22 2014-01-21 Eastman Kodak Company Negative-working lithographic printing plate precursors with IR dyes
US9029063B2 (en) 2011-09-22 2015-05-12 Eastman Kodak Company Negative-working lithographic printing plate precursors
CN102311355B (zh) * 2011-09-26 2014-02-05 扬州天和药业有限公司 罗本考昔的一种制备方法
GB201122113D0 (en) 2011-12-22 2012-02-01 Convergence Pharmaceuticals Novel compounds
US8679726B2 (en) 2012-05-29 2014-03-25 Eastman Kodak Company Negative-working lithographic printing plate precursors
US9063423B2 (en) 2013-02-28 2015-06-23 Eastman Kodak Company Lithographic printing plate precursors and use
US9201302B2 (en) 2013-10-03 2015-12-01 Eastman Kodak Company Negative-working lithographic printing plate precursor
GB201417500D0 (en) 2014-10-03 2014-11-19 Convergence Pharmaceuticals Novel use
GB201417499D0 (en) 2014-10-03 2014-11-19 Convergence Pharmaceuticals Novel use
GB201417497D0 (en) 2014-10-03 2014-11-19 Convergence Pharmaceuticals Novel use
US11583516B2 (en) 2016-09-07 2023-02-21 Trustees Of Tufts College Dash inhibitors, and uses related thereto
TWI727151B (zh) 2017-03-14 2021-05-11 日商生化學工業股份有限公司 關節疾患處置用組成物及含有該組成物的套組
ES2985871T3 (es) 2017-03-14 2024-11-07 Seikagaku Kogyo Co Ltd Composición para tratar artropatías y kit que incluye la misma
KR102069205B1 (ko) 2017-08-09 2020-01-22 연성정밀화학(주) 라타노프로스틴 부노드의 제조 방법 및 그를 위한 중간체
CN109694330B (zh) * 2017-10-24 2023-10-20 乳源瑶族自治县东阳光生物科技有限公司 一种酸的制备方法
WO2020021077A1 (en) 2018-07-27 2020-01-30 Krka, D.D., Novo Mesto A process for the preparation of polymorphic form of robenacoxib
CN109503399B (zh) * 2018-12-29 2021-12-24 江苏天和制药有限公司 一种罗本考昔的制备方法
CN110437090A (zh) * 2019-07-31 2019-11-12 江苏天和制药有限公司 一种罗本考昔三聚体及其制备方法
CN111807978B (zh) * 2020-07-29 2023-03-14 武汉川泰科技有限公司 一种罗贝考昔的制备方法
IL305573A (en) 2021-03-15 2023-10-01 Saul Yedgar HYALURONIC ACID-CONJUGATED DIPALMITOYL PHOSPHATIDYL ETHANOLAMINE IN COMBINATION WITH NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDs) FOR TREATING OR ALLEVIATING INFLAMMATORY DISEASES
US20250214927A1 (en) 2022-03-23 2025-07-03 Alivira Animal Health Limited An improved process for purification of robenacoxib
CN117886709B (zh) * 2023-12-26 2026-03-06 武汉回盛生物科技股份有限公司 一种罗贝考昔的合成方法
CN120004366B (zh) * 2025-04-18 2025-07-25 浙江九安检测科技有限公司 一种二噁英前处理过程中有机试剂的回收方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3895063A (en) 1965-04-08 1975-07-15 Ciba Geigy Corp Substituted Anilino Benzyl Alcohols
US3558690A (en) 1965-04-08 1971-01-26 Gelgy Chemical Corp Substituted derivatives of 2-anilinophenylacetic acids and a process of preparation
GB1166861A (en) 1966-01-15 1969-10-15 Aspro Nicholas Ltd New Diphenylamine Derivatives and Compositions containing them
US3652762A (en) 1970-04-14 1972-03-28 Ciba Geigy Corp Pharmaceutical compositions and methods employing substituted derivatives of 2-anilinophenylacetic acids and esters
US4173577A (en) 1970-09-09 1979-11-06 Ciba-Geigy Corporation Phenylacetohydroxamic acids
ES520813A0 (es) 1983-03-21 1984-05-16 Prodes Sa Procedimiento para la obtencion del ester del acido 2-(2,6-diclorofenil)amino bencenoacetico con acido glicolico.
DE3445011A1 (de) 1983-12-13 1985-06-13 Ciba-Geigy Ag, Basel Neues anilinderivat, verfahren zu seiner herstellung und seine verwendung
GR900100380A (el) * 1989-05-20 1991-10-10 Fisons Plc Μέ?οδος παρασκευής αντι-φλεγμονωδών παραγώγων αμινοφενόλης.
IT1256345B (it) 1992-08-20 1995-12-01 Esteri nitrici di derivati dell'acido 2-(2,6-di-alo-fenilammino) fenilacetico e procedimento per la loro preparazione
CA2192682A1 (en) 1994-06-29 1996-01-11 Alfred Sallmann New salts of 2-¬(2,6-dichlorophenyl)amine|phenylacetoxyacetic acid with organic basic cations
JPH0977664A (ja) 1995-09-13 1997-03-25 Yakult Honsha Co Ltd シクロオキシゲナーゼ−２特異的阻害剤及び抗炎症剤
CO4960662A1 (es) 1997-08-28 2000-09-25 Novartis Ag Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados

Also Published As

Publication number Publication date
PL194480B1 (pl) 2007-06-29
AR015157A1 (es) 2001-04-18
BR9812010A (pt) 2000-12-12
CY2007020I2 (el) 2012-01-25
CA2298033C (en) 2007-10-02
SI1007505T1 (en) 2003-10-31
NO326196B1 (no) 2008-10-13
NO20000943D0 (no) 2000-02-25
US6451858B2 (en) 2002-09-17
PT1007505E (pt) 2003-08-29
CA2298033A1 (en) 1999-03-11
AU743371B2 (en) 2002-01-24
DE69813570T2 (de) 2004-02-12
PE108099A1 (es) 1999-11-18
US20040122254A1 (en) 2004-06-24
KR100637296B1 (ko) 2006-10-23
CY2007020I1 (el) 2012-01-25
NZ502669A (en) 2002-02-01
LU91540I2 (fr) 2009-05-11
DE122007000035I1 (de) 2007-07-19
SK283773B6 (sk) 2004-01-08
CO4960662A1 (es) 2000-09-25
LU91346I2 (fr) 2007-09-11
ID23953A (id) 2000-06-08
HUP0002514A3 (en) 2002-11-28
DE122007000035I2 (de) 2010-07-01
CZ298522B6 (cs) 2007-10-24
FR09C0011I2 (2) 2011-04-01
DE122009000013I1 (de) 2009-06-25
AU9534098A (en) 1999-03-22
US6310099B1 (en) 2001-10-30
TR200000447T2 (tr) 2000-07-21
WO1999011605A8 (en) 2000-03-02
ATE237580T1 (de) 2003-05-15
CN1140500C (zh) 2004-03-03
US6727281B2 (en) 2004-04-27
HUP0002514A2 (hu) 2000-12-28
PL338357A1 (en) 2000-10-23
JP2001514244A (ja) 2001-09-11
ES2197508T3 (es) 2004-01-01
NL300379I1 (nl) 2009-05-06
CN1268112A (zh) 2000-09-27
CZ2000714A3 (cs) 2000-06-14
KR20010023344A (ko) 2001-03-26
US20020013369A1 (en) 2002-01-31
HU225774B1 (en) 2007-08-28
IL134498A0 (en) 2001-04-30
MY127881A (en) 2006-12-29
SK2472000A3 (en) 2000-09-12
DE69813570D1 (de) 2003-05-22
EP1007505A1 (en) 2000-06-14
US20020183391A1 (en) 2002-12-05
IL134498A (en) 2009-06-15
FR09C0011I1 (2) 2009-04-17
WO1999011605A1 (en) 1999-03-11
JP3704470B2 (ja) 2005-10-12
US6291523B1 (en) 2001-09-18
NO2009007I2 (no) 2010-06-07
EP1007505B1 (en) 2003-04-16
RU2186762C2 (ru) 2002-08-10
HK1031374A1 (en) 2001-06-15
US7115662B2 (en) 2006-10-03
NO20000943L (no) 2000-02-25
NO2009007I1 (no) 2009-04-06
NL300379I2 (nl) 2010-02-01
BR9812010B1 (pt) 2010-12-14
TWI250142B (en) 2006-03-01

Similar Documents

Publication Publication Date Title
DK1007505T3 (da) Visse 5-alkyl-2-arylaminophenyleddikesyrer og derivater
DE69703385D1 (de) Alkoxyessigsäure-derivate
NO990821D0 (no) Arylsulfonylamino-hydroksaminsyre-derivater
ATE248812T1 (de) Arylsulfonylhydroxamsäurederivate
DK1003720T3 (da) Aryloxyarylsulfonylaminohydroxamsyrederivater
EE9900069A (et) Propioonhappe derivaadid ja nende kasutamine
ATE238984T1 (de) Sulfonylaminocarbonsäuren
ATE225784T1 (de) Indan- oder dihydroindolderivate
DK0983251T3 (da) Anti-inflammatorisk piperazinylbenzyltetrazolderivater og mellemprodukter derfor
NO20000231D0 (no) Dolastatin-15-derivater
DK0906301T3 (da) Benzofurylderivater og anvendelsen deraf
NO984761D0 (no) Aminoisokinoliner og aminotienopyridinderivater og deres anvendelse som antiinflammatoriske midler
DK94897A (da) Propeller
TR199800117A3 (tr) Isaksazol- ve krotonasitamid türevleri ve bunlarin kullanimi.
PT878467E (pt) Acidos 6-aminotetra-hidroisoquinolinacarboxilicos e 7-aminotetra-hidroisoquinolinacarboxilicos substituidos
FI951101L (fi) 5-vinyyli- ja 5-etinyylikinoloni- ja -naftyridonikarboksyylihapot
DE69718338D1 (de) 3-alkoxyisoxazol-4-yl-substituierte 2-aminocarbonsäurederivate
NO984921D0 (no) Tienopyridinderivater og deres anvendelse
EE04061B1 (et) Metüleenbisfosfoonhappe derivaadid
FR2767567B3 (fr) Helice
ZA987785B (en) Certain 5-alkyl-2-arylaminophenilacetic acids and derivatives
ID17484A (id) Baling-baling
ID21104A (id) Baling-baling
FI973647L (fi) Hydroksihappo-, dikarboksyylihappo- ja aminohappoesterit ja niiden käyttö